Blinatumomab Trimer Formation - Insights from a Mechanistic PKPD Model on the Implications for Switching from Infusion to Subcutaneous Dosing Regimen in Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Poster Abstract
Objectives
Blinatumomab is a bispecific T-cell engager (BiTE) that binds to CD3 on T-cells and CD19 on B-cells. It has been approved for use in Acute lymphoblastic leukemia (ALL) with a regimen that requires constant infusion for four weeks per treatment cycle [1-4].